Xarelto approval by USFDA in orthopedic surgery- First Oral therapy for DVT prevention arrives in the US market
Xarelto 10mg/once daily is the first among the oral anticoagulants to win a USFDA approval for prevention of DVT (Deep Vein Thrombosis) in patients following hip or knee surgery. Earlier Pradaxa has failed to get an approval as it failed to show net clinical benefit over Lovenox. VTE prevention post orthopedic surgery is a small market~ $500m and despite entry of Lovenox generics, we anticipate Xarelto should be able to carve a decent share (~ 50%), driven by the robust efficacy demonstrated in clinical trials. Both Eliquis and Pradaxa have failed to show net clinical benefit over Lovenox US regimen in clinical trials for VTE prevention.
COMPANIES MENTIONED
PFE, BMY, BAYN, JNJ,
PFE, BMY, BAYN, JNJ,
